XTL Biopharmaceuticals Ltd (H2K2) — Strategic Asset Allocation Index
XTL Biopharmaceuticals Ltd (H2K2) has a Strategic Asset Allocation Index of 0.3% as of December 2024. Strategic assets (PP&E of €- plus long-term investments of €14.00K) total €14.00K, measured against net assets of €5.43 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See XTL Biopharmaceuticals Ltd (H2K2) balance sheet quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
XTL Biopharmaceuticals Ltd Strategic Asset Allocation Index (2016–2024)
This chart shows how XTL Biopharmaceuticals Ltd's Strategic Asset Allocation Index has evolved across 6 annual periods from 2016 to 2024. As of December 2024, the index stands at 0.3%, representing strategic assets of €14.00K against net assets of €5.43 Million EUR. For live market cap and overall valuation, see market value of XTL Biopharmaceuticals Ltd.
Annual Strategic Asset Allocation Index for XTL Biopharmaceuticals Ltd (2016–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for XTL Biopharmaceuticals Ltd from 2016 to 2024, covering 6 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See shareholders equity of XTL Biopharmaceuticals Ltd for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 0.3% | €14.00K | €- | €14.00K | €5.43 Million | ▲ +0.3 pp |
| 2023 | 0.0% | €0.00 | €- | €0.00 | €2.22 Million | ▼ 0.0 pp |
| 2021 | 0.0% | €1.00K | €1.00K | €- | €5.33 Million | ▼ 0.0 pp |
| 2020 | 0.0% | €2.00K | €2.00K | €- | €6.25 Million | ▲ +0.0 pp |
| 2019 | 0.0% | €2.00K | €2.00K | €- | €6.98 Million | ▼ -0.3 pp |
| 2016 | 0.4% | €10.00K | €10.00K | €- | €2.69 Million | — |